Epidemiology, Diagnosis, and Treatment of HIV-Associated Non-Hodgkin Lymphoma in Resource-Limited Settings
This article is part of Special Issue:
Matthew Ulrickson,
Oliver W. Press,
Corey Casper,
Corresponding Author
Matthew Ulrickson
Department of Medicine, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA washington.edu
Search for more papers by this authorOliver W. Press
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA fhcrc.org
Search for more papers by this authorCorey Casper
Vaccine and Infectious Disease, Public Health Sciences, and Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA fhcrc.org
Search for more papers by this authorMatthew Ulrickson,
Oliver W. Press,
Corey Casper,
Corresponding Author
Matthew Ulrickson
Department of Medicine, University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA washington.edu
Search for more papers by this authorOliver W. Press
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA fhcrc.org
Search for more papers by this authorCorey Casper
Vaccine and Infectious Disease, Public Health Sciences, and Clinical Research Divisions, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA fhcrc.org
Search for more papers by this authorAcademic Editor: Lisa K. Hicks
Abstract
Lymphoma was a common complication of HIV infection in the pre-antiretroviral era, and the incidence of HIV-associated lymphoma has dropped dramatically since the introduction of combination antiretroviral therapy (cART) in resource-rich regions. Conversely, lymphoma is an increasingly common complication of HIV infection in resource-limited settings where the prevalence of HIV infection is high. Relatively little is known, however, about the true incidence and optimal treatment regimens for HIV-associated lymphoma in resource-poor regions. We review the epidemiology, diagnosis, and treatment of HIV-associated non-Hodgkin lymphoma in developing nations and highlight areas for further research that may benefit care in both settings. Examples include risk modification and dose modification of chemotherapy based on HIV risk factors, improving our understanding of the current burden of disease through national cancer registries, and developing cost-effective hematopathological diagnostic strategies to optimize care delivery and maximize use of available chemotherapy.
References
- 1 Diffuse, undifferentiated non-Hodgkins lymphoma among homosexual males—United States, MMWR: Morbidity and Mortality Weekly Report. (1982) 31, no. 21, 277–279.
- 2 Ziegler J. L., Drew W. L., and Miner R. C., Outbreak of Burkitt′s-like lymphoma in homosexual men, The Lancet. (1982) 2, no. 8299, 631–633, 2-s2.0-0019970750.
- 3 Beral V. and Newton R., Overview of the epidemiology of immunodeficiency-associated cancers, Journal of the National Cancer Institute. (1998) no. 23, 1–6, 2-s2.0-0031616255.
- 4 Casper C., [email protected], The increasing burden of HIV-associated malignancies in resource-limited regions, Annual Review of Medicine. (2011) 62, 157–170, https://doi.org/10.1146/annurev-med-050409-103711.
- 5 Ledergerber B., Telenti A., and Egger M., Risk of HIV related Kaposi′s sarcoma and non-Hodgkin′s lymphoma with potent antiretroviral therapy: prospective cohort study, British Medical Journal. (1999) 318, no. 7201, 23–24, 2-s2.0-0033519782.
- 6 Besson C., Goubar A., Gabarre J., Rozenbaum W., Pialoux G., Châtelet F. P., Katlama C., Charlotte F., Dupont B., Brousse N., Huerre M., Mikol J., Camparo P., Mokhtari K., Tulliez M., Salmon-Céron D., Boué F., Costagliola D., and Raphaël M., Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy, Blood. (2001) 98, no. 8, 2339–2344, 2-s2.0-0035889139, https://doi.org/10.1182/blood.V98.8.2339.
- 7 Eltom M. A., Jemal A., Mbulaiteye S. M., Devesa S. S., and Biggar R. J., Trends in Kaposi′s sarcoma and non-Hodgkin′s lymphoma incidence in the United States from 1973 through 1998, Journal of the National Cancer Institute. (2002) 94, no. 16, 1204–1210, 2-s2.0-0037151374.
- 8 Shiels M. S., [email protected], Pfeiffer R. M., Gail M. H., Hall H. I., Li J., Chaturvedi A. K., Bhatia K., Uldrick T. S., Yarchoan R., Goedert J. J., and Engels E. A., Cancer burden in the HIV-infected population in the United States, Journal of the National Cancer Institute. (2011) 103, no. 9, 753–762, https://doi.org/10.1093/jnci/djr076.
- 9 Clumeck N., Sonnet J., and Taelman H., Acquired immunodeficiency syndrome in African patients, The New England Journal of Medicine. (1984) 310, no. 8, 492–497, 2-s2.0-0021368591.
- 10 Van de Perre P., Lepage P., and Rouvroy D., Acquired immunodeficiency syndrome in Rwanda, The Lancet. (1984) 2, no. 8394, 62–65, 2-s2.0-0021281103.
- 11 Parkin D. M., Wabinga H., Nambooze S., and Wabwire-Mangen F., AIDS-related cancers in Africa: maturation of the epidemic in Uganda, AIDS. (1999) 13, no. 18, 2563–2570, 2-s2.0-0033375474, https://doi.org/10.1097/00002030-199912240-00010.
- 12 Adeniji K. A. and Anjorin A. S., Peripheral lymphadenopathy in Nigeria, African journal of medicine and medical sciences. (2000) 29, no. 3-4, 233–237, 2-s2.0-0034280049.
- 13 Newton R., Ziegler J., Beral V., Mbidde E., Carpenter L., Wabinga H., Mbulaiteye S., Appleby P., Reeves G., and Jaffe H., A case-control study of human immunodeficiency virus infection and cancer in adults and children residing in Kampala, Uganda, International Journal of Cancer. (2001) 92, no. 5, 622–627, 2-s2.0-0035371665, https://doi.org/10.1002/1097-0215(20010601)92:5<622::AID-IJC1256>3.0.CO;2-K.
- 14 Sitas F., Pacella-Norman R., Carrara H., Patel M., Ruff P., Sur R., Jentsch U., Hale M., Rowji P., Saffer D., Connor M., Bull D., Newton R., and Beral V., The spectrum of HIV-1 related cancers in South Africa, International Journal of Cancer. (2000) 88, no. 3, 489–492, 2-s2.0-0033814565, https://doi.org/10.1002/1097-0215(20001101)88:3<489::AID-IJC25>3.0.CO;2-Q.
- 15 Stein L., Urban M. I., O′Connell D., Xue Q. Y., Beral V., Newton R., Ruff P., Donde B., Hale M., Patel M., and Sitas F., The spectrum of human immunodeficiency virus-associated cancers in a South African black population: results from a case-control study, 1995–2004, International Journal of Cancer. (2008) 122, no. 10, 2260–2265, 2-s2.0-42149174980, https://doi.org/10.1002/ijc.23391.
- 16 Parkin D. M., Garcia-Giannoli H., Raphael M., Martin A., Katangole-Mbidde E., Wabinga H., and Ziegler J., Non-Hodgkin lymphoma in Uganda: a case-control study, AIDS. (2000) 14, no. 18, 2929–2936, 2-s2.0-0034521377, https://doi.org/10.1097/00002030-200012220-00015.
- 17 Naresh K. N., [email protected], Raphael M., Ayers L., Hurwitz N., Calbi V., Rogena E., Sayed S., Sherman O., Ibrahim H. A.H., Lazzi S., Mourmouras V., Rince P., Githanga J., Byakika B., Moshi E., Durosinmi M., Olasode B. J., Oluwasola O. A., Akang E. E., Akenòva Y., Adde M., Magrath I., and Leoncini L., [email protected], Lymphomas in sub-Saharan Africa—what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research?, British Journal of Haematology. (2011) 154, no. 6, 696–703, https://doi.org/10.1111/j.1365-2141.2011.08772.x.
- 18 Orem J., Otieno M. W., and Remick S. C., AIDS-associated cancer in developing nations, Current Opinion in Oncology. (2004) 16, no. 5, 468–476, 2-s2.0-4344693914, https://doi.org/10.1097/00001622-200409000-00010.
- 19 Wabinga H. R., Parkin D. M., Wabwire-Mangen F., and Nambooze S., Trends in cancer incidence in Kyadondo County, Uganda, 1960–1997, British Journal of Cancer. (2000) 82, no. 9, 1585–1592, 2-s2.0-0034127979.
- 20 Parkin D. M., Nambooze S., Wabwire-Mangen F., and Wabinga H. R., Changing cancer incidence in Kampala, Uganda, 1991–2006, International Journal of Cancer. (2010) 126, no. 5, 1187–1195, 2-s2.0-74049147777, https://doi.org/10.1002/ijc.24838.
- 21 Achenbach C. J., Cole S. R., Kitahata M. M., Casper C., Willig J. H., Mugavero M. J., and Saag M. S., Mortality after cancer diagnosis in HIV-infected individuals treated with antiretroviral therapy, AIDS. (2011) 25, no. 5, 691–700, 2-s2.0-78650030879, https://doi.org/10.1097/QAD.0b013e3283437f77.
- 22 Bateganya M. H., [email protected], Stanaway J., Brentlinger P. E., Magaret A. S., Wald A., Orem J., and Casper C., Predictors of survival after a diagnosis of non-Hodgkin lymphoma in a resource-limited setting: a retrospective study on the impact of HIV infection and its treatment, Journal of Acquired Immune Deficiency Syndromes. (2011) 56, no. 4, 312–319, https://doi.org/10.1097/QAI.0b013e31820c011a.
- 23 Lester J. F., Dojcinov S. D., Attanoos R. L., O′Brien C. J., Maughan T. S., Toy E. T., and Poynton C. H., The clinical impact of expert pathological review on lymphoma management: a regional experience, British Journal of Haematology. (2003) 123, no. 3, 463–468, 2-s2.0-0242266440, https://doi.org/10.1046/j.1365-2141.2003.04629.x.
- 24 Othieno-Abinya N. A., Abwao H. O., Maina J. M. D., Nyabola L. O., Opiyo A., Njuguna E., Ndege P., and Musibi A., Non-Hodgkin′s lymphomas at Kenyatta the National Hospital Nairobi in the 1990′s, East African Medical Journal. (2004) 81, no. 9, 450–458, 2-s2.0-16644377757.
- 25 Parkins E. et al., UK-based real-time lymphoproliferative disorder diagnostic service to improve the management of patients in Ghana, Journal of Hematopathology. (2009) 2, no. 3, 143–149.
- 26 Mwanda W. O., Orem J., Fu P., Banura C., Kakembo J., Onyango C. A., Ness A., Reynolds S., Johnson J. L., Subbiah V., Bako J., Wabinga H., Abdallah F. K., Meyerson H. J., Whalen C. C., Lederman M. M., Black J., Ayers L. W., Katongole-Mbidde E., and Remick S. C., Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin′s lymphoma in East Africa, Journal of Clinical Oncology. (2009) 27, no. 21, 3480–3488, 2-s2.0-70249145839, https://doi.org/10.1200/JCO.2008.18.7641.
- 27 Naresh K. N., [email protected], Ibrahim H. A. H., Lazzi S., Rince P., Onorati M., Ambrosio M. R., Bilhou-Nabera C., Amen F., Reid A., Mawanda M., Calbi V., Ogwang M., Rogena E., Byakika B., Sayed S., Moshi E., Mwakigonja A., Raphael M., Magrath I., and Leoncini L., [email protected], Diagnosis of Burkitt lymphoma using an algorithmic approach - applicable in both resource-poor and resource-rich countries, British Journal of Haematology. (2011) 154, no. 6, 770–776, https://doi.org/10.1111/j.1365-2141.2011.08771.x.
- 28 Tumwine L. K., Agostinelli C., Campidelli C., Othieno E., Wabinga H., Righi S., Falini B., Piccaluga P. P., Byarugaba W., and Pileri S. A., Immunohistochemical and other prognostic factors in B cell non Hodgkin lymphoma patients, Kampala, Uganda, BMC Clinical Pathology. (2009) 9, article 11, 2-s2.0-76149097568, https://doi.org/10.1186/1472-6890-9-11.
- 29 Jones T. J., Goad N. A. G., Muir K. R., Parkes S. E., Evans C. D., and Mann J. R., Immunophenotypic analysis of childhood Burkitt′s lymphoma in the West Midlands 1957–1986, Journal of Clinical Pathology. (1995) 48, no. 1, 22–25, 2-s2.0-0028900712.
- 30 Younes A., Bartlett N. L., Leonard J. P., Kennedy D. A., Lynch C. M., Sievers E. L., and Forero-Torres A., Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas, The New England Journal of Medicine. (2010) 363, no. 19, 1812–1821, 2-s2.0-78049515807, https://doi.org/10.1056/NEJMoa1002965.
- 31 Ziegler J. L., Beckstead J. A., and Volberding P. A., Non-Hodgkin′s lymphoma in 90 homosexual men. Relation to generalized lymphadenopathy and the acquired immunodeficiency syndrome, The New England Journal of Medicine. (1984) 311, no. 9, 565–570, 2-s2.0-0021713481.
- 32 Gill P. S., Levine A. M., Krailo M., Rarick M. U., Loureiro C., Deyton L., Meyer P., and Rasheed S., AIDS-related malignant lymphoma: results of prospective treatment trials, Journal of Clinical Oncology. (1987) 5, no. 9, 1322–1328, 2-s2.0-0023585220.
- 33 Kaplan L. D., Abrams D. I., Feigal E., McGrath M., Kahn J., Neville P., Ziegler J., and Volberding P. A., AIDS-associated non-Hodgkin′s lymphoma in San Francisco, Journal of the American Medical Association. (1989) 261, no. 5, 719–724, 2-s2.0-0024499040.
- 34 Kaplan L. D., Straus D. J., Testa M. A., Von Roenn J., Dezube B. J., Cooley T. P., Herndier B., Northfelt D. W., Huang J., Tulpule A., and Levine A. M., Low-dose compared with standard-dose m-BACOD chemotherapy for non- Hodgkin′s lymphoma associated with human immunodeficiency virus infection, The New England Journal of Medicine. (1997) 336, no. 23, 1641–1648, https://doi.org/10.1056/NEJM199706053362304.
- 35 Mounier N., Spina M., Gabarre J., Raphael M., Rizzardini G., Golfier J. B., Vaccher E., Carbone A., Coiffier B., Chichino G., Bosly A., Tirelli U., and Gisselbrecht C., AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapy, Blood. (2006) 107, no. 10, 3832–3840, 2-s2.0-33646565996, https://doi.org/10.1182/blood-2005-09-3600.
- 36 Moh R., Danel C., Sorho S., Sauvageot D., Anzian A., Minga A., Ba Gomis O., Kanga C., Inwoley A., Gabillard D., Bissagnene E., Salamon R., and Anglaret X., Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d′Ivoire, Antiviral Therapy. (2005) 10, no. 5, 615–624, 2-s2.0-24044545281.
- 37 Otieno M. W., Remick S. C., and Whalen C., Adult burkitt′s lymphoma in patients with and without human immunodeficiency virus infection in Kenya, International Journal of Cancer. (2001) 92, no. 5, 687–691, 2-s2.0-0035371853, https://doi.org/10.1002/1097-0215(20010601)92:5<687::AID-IJC1246>3.0.CO;2-Z.
- 38 Kaplan L. D., Lee J. Y., Ambinder R. F., Sparano J. A., Cesarman E., Chadburn A., Levine A. M., and Scadden D. T., Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010, Blood. (2005) 106, no. 5, 1538–1543, 2-s2.0-23944508056, https://doi.org/10.1182/blood-2005-04-1437.
- 39 Dunleavy K., Little R. F., Pittaluga S., Grant N., Wayne A. S., Carrasquillo J. A., Steinberg S. M., Yarchoan R., Jaffe E. S., and Wilson W. H., The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma, Blood. (2010) 115, no. 15, 3017–3024, 2-s2.0-77951045229, https://doi.org/10.1182/blood-2009-11-253039.
- 40 Sparano J. A., Lee J. Y., Kaplan L. D., Levine A. M., Ramos J. C., Ambinder R. F., Wachsman W., Aboulafia D., Noy A., Henry D. H., Von Roenn J., Dezube B. J., Remick S. C., Shah M. H., Leichman L., Ratner L., Cesarman E., Chadburn A., and Mitsuyasu R., Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma, Blood. (2010) 115, no. 15, 3008–3016, 2-s2.0-77951045842, https://doi.org/10.1182/blood-2009-08-231613.
- 41 Remick S. C., Sedransk N., Haase R., Craffey M., Subramanian N., Dowlati A., Nazeer T., Ramnes C., Blanchard C., Mastrianni D., Balducci L., Horton J., and Ruckdeschel J. C., Oral combination chemotherapy in the management of AIDS-related lymphoproliferative malignancies, Drugs. (1999) 58, no. 3, supplement, 99–107, 2-s2.0-17144440057.
- 42 Centers for Disease Control and Prevention (CDC), Progress toward strengthening national blood transfusion services—14 countries, 2008–2010., MMWR: Morbidity and Mortality Weekly Report. (2011) 60, no. 46, 1577–1582.
- 43 Sloan J. M. and Ballen K., SCT in Jehovah′s Witnesses: the bloodless transplant, Bone Marrow Transplantation. (2008) 41, no. 10, 837–844, 2-s2.0-44449168259, https://doi.org/10.1038/bmt.2008.5.
- 44 Gill P. S., Loureiro C., Bernstein-Singer M., Rarick M. U., Sattler F., and Levine A. M., Clinical effect of glucocorticoids on Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS), Annals of Internal Medicine. (1989) 110, no. 11, 937–940, 2-s2.0-0024376165.
- 45 Kobashi Y. and Matsushima T., Clinical analysis of pulmonary tuberculosis in association with corticosteroid therapy, Internal Medicine. (2002) 41, no. 12, 1103–1110, 2-s2.0-0036971842.
- 46 Cheng A. L., Steroid-free chemotherapy decreases the risk of hepatitis flare-up in hepatitis B virus carriers with non-Hodgkin′s lymphoma, Blood. (1996) 87, no. 3, 2-s2.0-0030059941.
- 47 Chen X. Q., Peng J. W., Lin G. N., Li M., and Xia Z. J., [email protected], The effect of prophylactic lamivudine on hepatitis B virus reactivation in HBsAg-positive patients with diffuse large B-cell lymphoma undergoing prolonged rituximab therapy, Medical Oncology. In presshttps://doi.org/10.1007/s12032-011-9974-0.
- 48 Seremba E., Ocama P., Opio C. K., Kagimu M., Yuan H. J., Attar N., Thomas D. L., and Lee W. M., Validity of the rapid strip assay test for detecting HBsAg in patients admitted to hospital in Uganda, Journal of Medical Virology. (2010) 82, no. 8, 1334–1340, 2-s2.0-77956569649, https://doi.org/10.1002/jmv.21813.
- 49 Knaul F. M., Frenk, Julio, and Shulman, Lawrence for the Global Task Force on Expanded Access to Cancer Care and Control in Developing Countries, Closing the Cancer Divide: A Blueprint to Expand Access in Low and Middle Income Countries, Harvard Global Equity Initiative, Boston, Mass, USA, October 2011.
- 50 Bloom D. E., Cafiero E. T., Jané-Llopis E. et al., The Global Economic Burden of Noncommunicable Diseases, 2011, World Economic Forum, Geneva, Switzerland.
- 51 Jones L. A., Chilton J. A., Hajek R. A., Iammarino N. K., and Laufman L., Between and within: international perspectives on cancer and health disparities, Journal of Clinical Oncology. (2006) 24, no. 14, 2204–2208, 2-s2.0-33646576857, https://doi.org/10.1200/JCO.2005.05.1813.
